ReviewHaematologica2015
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.
Review in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Trial
- ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML.Frontiers in immunology · 2026Article
- Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.Signal transduction and targeted therapy · 2024Review
- Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome.International journal of hematology · 2024Article
- Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma.Pathogens & immunity · 2024Review
- Improved Antitumor Effect of NK Cells Activated by Neutrophils in a Bone Marrow Transplant Model.Mediators of inflammation · 2023Article
- Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.Life (Basel, Switzerland) · 2021Review
- Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!Blood reviews · 2018Review
- Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2018Review
- Developing T-cell therapies for lymphoma without receptor engineering.Blood advances · 2017Review
- Developing T-cell therapies for lymphoma without receptor engineering.Hematology. American Society of Hematology. Education Program · 2017Review
- Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.The Journal of experimental medicine · 2017Article
- 'Trained immunity': consequences for lymphoid malignancies.Haematologica · 2016Review
- [Donor- derived CD19 chimeric antigen receptor T cells for relapsed B cell malignancies after allogeneic hematopoietic stem cell transplantations].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.Oncoimmunology · 2016Article
- Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications.Frontiers in immunology · 2016Review
- Resolutions for the New Year.Haematologica · 2016Article
- Personalized medicine in adult acute lymphoblastic leukemia.Haematologica · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hematopoietic stem cell transplantation has revolutionized the treatment of hematologic malignancies, but infection, graft-versus-host disease and relapse are still important problems. Calcineurin inhibitors, T-cell depletion strategies, and immunomodulators have helped to prevent graft-versus-host disease, but have a negative impact on the graft-versus-leukemia effect. T cells and natural killer cells are both thought to be important in the graft-versus-leukemia effect, and both cell types are amenable to ex vivo manipulation and clinical manufacture, making them versatile immunotherapeutics. We provide an overview of these immunotherapeutic strategies following hematopoietic stem cell transplantation, with discussions centered on natural killer and T-cell biology. We discuss the contributions of each cell type to graft-versus-leukemia effects, as well as the current research directions in the field as related to adoptive cell therapy after hematopoietic stem cell transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.